{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:53:05Z","timestamp":1785037985220,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Scutellarin, a flavonoid derived from the plant Erigeron breviscapus, is currently widely used to treat cerebrovascular diseases, liver-related diseases, and hyperlipidemia in china and other East Asian countries. This study was to investigate the effect of scutellarin on the uptake of rosuvastatin in HEK293T cells expressing human organic anion transporting polypeptide 1B3 (hOATP1B3) and rat OATP1B2 (rOATP1B2), respectively, and the effect of scutellarin on the pharmacokinetics of rosuvastatin in rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The newly established HEK293T cells expressing hOATP1B3 and rOATP1B2 were used to examine the effects of scutellarin and positive controls on <jats:italic>in vitro<\/jats:italic> rosuvastatin transport. After co-feeding with scutellarin, the rosuvastatin area under the plasma concentration-time curve (AUC<jats:sub>0\u201324h<\/jats:sub>), the peak plasma drug concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>), elimination half-life (<jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub>), time to reach <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> (<jats:italic>t<\/jats:italic><jats:sub>max<\/jats:sub>), clearance (CL) and apparent clearance (CL\/F) of rosuvastatin were determined in rats.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Scutellarin inhibited hOATP1B3- and rOATP1B2-mediated rosuvastatin uptake (IC50: 45.54\u2009\u00b1\u20096.67\u00a0\u03bcM and 27.58\u2009\u00b1\u20093.97\u00a0\u03bcM) <jats:italic>in vitro<\/jats:italic> in a concentration-dependent manner. After co-feeding with scutellarin, the AUC<jats:sub>0\u201324h<\/jats:sub> and <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> of rosuvastatin in rats increased to 27.4% and 37.7%, respectively. The <jats:italic>t<\/jats:italic><jats:sub>1\/2<\/jats:sub> and <jats:italic>t<\/jats:italic><jats:sub>max<\/jats:sub> of rosuvastatin showed no significant change. Moreover, scutellarin caused 29.2% and 28.1% decrease in the CL and CL\/F of rosuvastatin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Scutellarin may inhibit the hOATP1B3- and rOATP1B2-mediated transport of rosuvastatin <jats:italic>in vitro<\/jats:italic>, and exerts a moderate inhibitory effect on the pharmacokinetics of rosuvastatin in rats. Scutellarin is highly likely to participate in drug-drug interactions, as mediated by OATP1B3 in humans.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11095-020-02950-5","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T19:02:35Z","timestamp":1603998155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3"],"prefix":"10.1007","volume":"37","author":[{"given":"Jianming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"2950_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1142\/S0192415X1750001X","volume":"45","author":"WJ Yu","year":"2017","unstructured":"Yu WJ, Ma MY, Chen XM, Min JY, Li LR, Zheng YF, et al. Traditional Chinese medicine and constitutional medicine in China, Japan and Korea: a comparative study. Am J Chinese Med. 2017;45:1\u201312.","journal-title":"Am J Chinese Med"},{"key":"2950_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pharmthera.2018.05.006","volume":"190","author":"PW Li","year":"2018","unstructured":"Li PW, Qiang M. Clinical benefits and pharmacology of scutellarin: a comprehensive review. Pharmacol Ther. 2018;190:105\u201327.","journal-title":"Pharmacol Ther"},{"key":"2950_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fphar.2017.00289","volume":"8","author":"J Gao","year":"2017","unstructured":"Gao J, Chen G, He H, Liu C, Xiong X, Li J, et al. Therapeutic effects of Breviscapine in cardiovascular diseases: a review. Front Pharmacol. 2017;8:289.","journal-title":"Front Pharmacol"},{"key":"2950_CR4","first-page":"3141","volume":"38","author":"W Yang","year":"2013","unstructured":"Yang W, Li L, Xie YM, Zhuang Y, Yang W. Treatment outcomes of parenterally administered dengzhan xixin for treatment of cerebral infaction based on real world hospital injection system data. Zhongguo Zhong Yao Za Zhi. 2013;38:3141\u20139.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"2950_CR5","first-page":"576","volume":"34","author":"JM Liu","year":"2018","unstructured":"Liu JM, Yang YX, Ye Y. Effect of scutellarin on the plasma concentration and tissue distributions of rosuvastatin in rats. Chin J Clin Pharmacol. 2018;34:576\u20139.","journal-title":"Chin J Clin Pharmacol"},{"key":"2950_CR6","first-page":"247","volume":"11","author":"SS Lin","year":"2015","unstructured":"Lin SS, Tsai CL, Tu CY, Hsieh CL. Reducing drug\u2013herb interaction risk with a computerized reminder system. Ther Clin Risk Manag. 2015;11:247\u201353.","journal-title":"Ther Clin Risk Manag"},{"key":"2950_CR7","first-page":"2996","volume":"20","author":"BY Han","year":"2014","unstructured":"Han BY, Yao YH. Pharmacokinetic interaction and the mechanisms of combination of Chinese and western medicines. Medical Recapitulate. 2014;20:2996\u20138.","journal-title":"Medical Recapitulate"},{"issue":"9","key":"2950_CR8","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1007\/s11095-013-1007-6","volume":"30","author":"RM Mitchell","year":"2013","unstructured":"Mitchell RM, Hartmut J. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res. 2013;30(9):2174\u201387.","journal-title":"Pharm Res"},{"key":"2950_CR9","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.tips.2012.03.001","volume":"33","author":"A Tornio","year":"2012","unstructured":"Tornio A, Niemi M, Neuvonen PJ, Backman JT. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol. 2012;33:312\u201322.","journal-title":"Trends Pharmacol"},{"key":"2950_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/pr.113.007518","volume":"65","author":"J K\u00f6nig","year":"2013","unstructured":"K\u00f6nig J, Muller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65:944\u201366.","journal-title":"Pharmacol Rev"},{"key":"2950_CR11","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1124\/dmd.112.047183","volume":"40","author":"C Gao","year":"2012","unstructured":"Gao C, Zhang H, Guo Z, You T, Chen X, Zhong D. Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012;40:2009\u201320.","journal-title":"Drug Metab Dispos"},{"key":"2950_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/ijms19030855","volume":"19","author":"K Alam","year":"2018","unstructured":"Alam K, Crowe A, Wang XY, Zhang PY, Ding K, Li L, et al. Regulation of organic anion transporting polypeptides (OATP) 1B1- and OATP1B3-mediated transport: an updated review in the context of OATP-mediated drug-drug interactions. Int J Mol Sci. 2018;19:855.","journal-title":"Int J Mol Sci"},{"key":"2950_CR13","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/s41598-020-58303-0","volume":"10","author":"JM Liu","year":"2020","unstructured":"Liu JM, Guo Y, Liu KQ, Ye XY, Wang F, Xu Y, et al. Scutellarin inhibition of the rosuvastatin uptake in rat hepatocytes and the competition for organic anion transporting polypeptide 1B1 in HEK293T cells. Sci Rep. 2020;10:1308\u201316.","journal-title":"Sci Rep"},{"key":"2950_CR14","doi-asserted-by":"publisher","first-page":"23161","DOI":"10.1074\/jbc.M001448200","volume":"275","author":"J K\u00f6nig","year":"2000","unstructured":"K\u00f6nig J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem. 2000;275:23161\u20138.","journal-title":"J Biol Chem"},{"key":"2950_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1053\/jhep.2002.34133","volume":"36","author":"SR Vavricka","year":"2002","unstructured":"Vavricka SR, Van MJ, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002;36:164\u201372.","journal-title":"Hepatology."},{"key":"2950_CR16","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36:2014\u201323.","journal-title":"Drug Metab Dispos"},{"key":"2950_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0014-5793(00)01596-9","volume":"474","author":"V Cattori","year":"2000","unstructured":"Cattori V, Hagenbuch B, Hagenbuch N, Stieger B, Ha R, Winterhalter KE, et al. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. FEBS Lett. 2000;474:242\u20135.","journal-title":"FEBS Lett"},{"key":"2950_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1124\/mol.108.046458","volume":"74","author":"Z Hani","year":"2008","unstructured":"Hani Z, Henriette E, Rommel G, Tirona, Melissa LC, Leslie AO, et al. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (oatp1b2\/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharm. 2008;74:320\u20139.","journal-title":"Mol Pharm."},{"key":"2950_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41467-018-02883-z","volume":"9","author":"XN Liu","year":"2018","unstructured":"Liu XN, Cheng J, Zhang GG, Ding WT, Duan LG, Yang J. Engineering yeast for the production of breviscapine by genomic analysis and synthetic biology approaches. Nat Commun. 2018;9:448\u201356.","journal-title":"Nat Commun"},{"key":"2950_CR20","first-page":"4","volume":"21","author":"JM Liu","year":"2017","unstructured":"Liu JM, Guo YM, Yang YX, Wang J, Wang F. Influence of scutellarin on intestinal absorption of rosuvastatin in rats. Asia-pacific tradional medicine. 2017;21:4\u20138.","journal-title":"Asia-pacific tradional medicine"},{"key":"2950_CR21","doi-asserted-by":"crossref","unstructured":"Dong JJ, Olaleye OE, Jiang RR, Li J, Lu C, Du FF, Xu F, Yang JL, Wang FQ, Jia WW, Li C. Glycyrrhizin has a high likelihood to be a victim of drug\u2013drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1\/1B3. Br J Pharmacol. 2018; 175:3486\u2013503.","DOI":"10.1111\/bph.14393"},{"key":"2950_CR22","first-page":"1688","volume":"32","author":"HS You","year":"2007","unstructured":"You HS, Dong YL, Xing JF, Zhang CL, Wang MY. Pharmacokinetic and tissue distribution study of scutellarin in rats. China Journal of Chinese Materia Medica. 2007;32:1688\u201392.","journal-title":"China Journal of Chinese Materia Medica"},{"key":"2950_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1124\/dmd.106.009779","volume":"34","author":"XY Chen","year":"2006","unstructured":"Chen XY, Cui L, Duan XT, Ma B, Zhong DF. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metab Dispos. 2006;34:1345\u201352.","journal-title":"Drug Metab Dispos"},{"key":"2950_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pharmthera.2018.10.007","volume":"195","author":"O Stefan","year":"2019","unstructured":"Stefan O. Organic anion transporting polypeptide (OATP) transporter expression, localization and function in the human intestine. Pharmacol Ther. 2019;195:39\u201353.","journal-title":"Pharmacol Ther"},{"key":"2950_CR25","doi-asserted-by":"crossref","unstructured":"Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793\u2013806.","DOI":"10.1053\/j.gastro.2006.02.034"},{"key":"2950_CR26","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1053\/j.gastro.2018.07.031","volume":"155","author":"Q Pan","year":"2018","unstructured":"Pan Q, Zhang X, Zhang L, Cheng Y, Zhao N. Solute carrier organic anion transporter family member 3A1 is a bile acid efflux transporter in cholestasis. Gastroenterology. 2018;155:1578\u201392.","journal-title":"Gastroenterology."},{"key":"2950_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/hep.23984","volume":"53","author":"IL Csanaky","year":"2011","unstructured":"Csanaky IL, Lu H, Zhang Y, Ogura K, Choudhuri S, Klaassen CD. Organicanion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice. Hepatology. 2011;53:272\u201381.","journal-title":"Hepatology."},{"key":"2950_CR28","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1177\/0091270011422815","volume":"52","author":"MK DeGorter","year":"2012","unstructured":"DeGorter MK, Urquhart BL, Gradhand U, Tirona RG, Kim RB. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2\u2212\/\u2212mice and intraindividual variability in human subjects. J Clin Pharmacol. 2012b;52:1689\u201397.","journal-title":"J Clin Pharmacol"},{"key":"2950_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1124\/mol.108.046458","volume":"74","author":"H Zaher","year":"2008","unstructured":"Zaher H, Schwabedissen HE, Tirona RG, Cox ML, Obert LA. Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2\/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol. 2008;74:320\u20139.","journal-title":"Mol Pharmacol"},{"key":"2950_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/dmd.113.054783","volume":"42","author":"JW Higgins","year":"2014","unstructured":"Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK. Utility of Oatp1a\/1b-knockout and OATP1B1\/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin,simvastatin, and carboxydichlorofluorescein. Drug Metab Dispos. 2014;42:182\u201392.","journal-title":"Drug Metab Dispos"},{"key":"2950_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0005-2736(02)00633-8","volume":"1609","author":"B Hagenbuch","year":"2003","unstructured":"Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003;1609:1\u201318.","journal-title":"Biochim Biophys Acta"},{"key":"2950_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","volume":"447","author":"B Hagenbuch","year":"2004","unstructured":"Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP\/SLC21 family: phylogenetic classification as OATP\/SLCO superfamily, new nomenclature and molecular\/functional properties. Pflug Arch. 2004;447:653\u201365.","journal-title":"Pflug Arch"},{"key":"2950_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2133\/dmpk.DMPK-12-RV-099","volume":"28","author":"IY Gong","year":"2013","unstructured":"Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet. 2013;28:4\u201318.","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02950-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-020-02950-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-020-02950-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T16:26:26Z","timestamp":1612196786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-020-02950-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2950"],"URL":"https:\/\/doi.org\/10.1007\/s11095-020-02950-5","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"28 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"232"}}